Showing results (1131-1140 of 1,547) with videos related to

Sort By:
Pageof 155
Nature Biotechnology|November 8, 2016
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rateMark M Stevens, Cecile L Maire, Nigel Chou, et al.
International Journal of Radiation Oncology, Biology, Physics|April 6, 2015
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patientsNils D Arvold, Shyam K Tanguturi, Ayal A Aizer, et al.
The Lancet. Oncology|September 30, 2021
Leveraging external data in the design and analysis of clinical trials in neuro-oncologyRifaquat Rahman, Steffen Ventz, Jon McDunn, et al.
Neuro-Oncology|February 11, 2004
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyMichael D Prados, W K A Yung, Kurt A Jaeckle, et al.
AJNR. American Journal of Neuroradiology|May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Science (New York, N.Y.)|October 26, 2002
Reversal of bone loss in mice by nongenotropic signaling of sex steroidsS Kousteni, J R Chen, T Bellido, et al.
Neuro-Oncology|October 10, 2015
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II studyNicholas Butowski, Howard Colman, John F De Groot, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|November 5, 2020
[Exploratory research on developing lung cancer risk prediction model in female non-smokers]Z Y Lyu, N Li, S H Chen, et al.
The Lancet. Oncology|June 6, 2020
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groupCraig Erker, Benita Tamrazi, Tina Y Poussaint, et al.
Neuro-Oncology Advances|August 9, 2023
Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppressionDavy Deng, Lubna Hammoudeh, Gilbert Youssef, et al.
Pageof 155